Activation of monoaminergic system contributes to the antidepressant- and anxiolytic-like effects of J147

Xiaoyu Pan,Ling Chen,Wen Xu,Shihui Bao,Jun Wang,Xiao Cui,Shichao Gao,Kaiping Liu,Shivani Avasthi,Meixi Zhang,Ruijie Chen
DOI: https://doi.org/10.1016/j.bbr.2021.113374
IF: 3.352
2021-08-01
Behavioural Brain Research
Abstract:<p>Major depressive disorder (MDD) is a severe mental disorder, which is closely related to the deficiency of monoamine neurotransmitters. Our previous study suggested that acute treatment with J147, a novel curcumin derivative, produced antidepressant-like effects in mouse model of depression by regulation of 5-HT receptor subtypes. However, it is still unknown whether the antidepressant-like effects of J147 are involved in activation of central monoaminergic system. In this study, a series of classical behavior tests were employed to assess the involvement of monoaminergic system in antidepressant- and anxiolytic-like effects after sub-acute treatment of mice with J147 for 3 days. The results suggested that J147 at 10 mg/kg significantly reduced the immobility time in both the tail suspension and forced swimming tests, but didn't show effects in the sucrose preference test. Similarly, sub-acute treatment of J147 did not induce amelioration in novelty suppressed feeding test. J147 increased duration and crossing time in the central area, but did not show significant change in rearing counts in the open field test. In neurochemical assays, studies suggested that serotonin and noradrenaline levels were significantly increased in the frontal cortex and hippocampus after treatment of J147 by the high-performance liquid chromatography (HPLC) with an electrochemical detector. Moreover, J147-induced significant inhibition of monoamine oxidase A activity. These findings suggest that the antidepressant- and anxiolytic-like effects of J147 might be related to the monoaminergic system by the evidence that high dose of J147 inhibits monoamine oxidase (MAO)-A activity and increases synaptic monoamines in the mouse brain.</p>
behavioral sciences,neurosciences
What problem does this paper attempt to address?
The main issue this paper attempts to address is whether J147 (a novel curcumin derivative) has antidepressant and anxiolytic-like effects in subacute treatment, and further elucidate whether these effects are related to the activation of the monoaminergic system. Specifically, the researchers evaluated the effects of J147 on depressive and anxiety-like behaviors in mice through a series of classical behavioral tests and neurochemical analyses, as well as its regulatory effects on brain monoamine neurotransmitter levels and monoamine oxidase activity. ### Main Research Questions: 1. **Does J147 have antidepressant and anxiolytic-like effects?** - The researchers evaluated the effects of J147 on depressive and anxiety-like behaviors in mice through behavioral tests such as the Forced Swim Test (FST), Tail Suspension Test (TST), Novelty-Suppressed Feeding Test (NSFT), and Open Field Test (OFT). 2. **Does J147 exert its antidepressant and anxiolytic-like effects by activating the monoaminergic system?** - Using high-performance liquid chromatography (HPLC) and electrochemical detection, the researchers measured the levels of 5-hydroxytryptamine (5-HT), norepinephrine (NA), and dopamine (DA) and their metabolites in the prefrontal cortex, hippocampus, and amygdala of mice after J147 treatment. - Additionally, the researchers examined the effects of J147 on the activity of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). ### Research Background: - **Major Depressive Disorder (MDD)** is a severe psychological disorder affecting over 322 million people worldwide, with an increasing incidence rate each year. - Currently used antidepressants such as tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and selective serotonin reuptake inhibitors (SSRIs) or selective serotonin and norepinephrine reuptake inhibitors (SNRIs) have issues with delayed efficacy and severe adverse effects. - The increase of monoamine neurotransmitters (such as 5-HT, NA, and DA) in the brain is the main mechanism of action of traditional antidepressants, thus studying the effects of J147 on the monoaminergic system is of great significance. ### Research Methods: - **Animal Model**: Experiments were conducted using male ICR mice. - **Administration Method**: J147 was administered via gavage for 3 consecutive days. - **Behavioral Tests**: Included Forced Swim Test (FST), Tail Suspension Test (TST), Novelty-Suppressed Feeding Test (NSFT), Open Field Test (OFT), and Sucrose Preference Test (SPT). - **Neurochemical Analysis**: Levels of monoamine neurotransmitters and their metabolites in the prefrontal cortex, hippocampus, and amygdala were measured using HPLC and electrochemical detection. - **Monoamine Oxidase Activity Assay**: MAO-A and MAO-B activities in different brain regions were measured using optimized protocols. ### Results: - **Behavioral Test Results**: - J147 significantly reduced immobility time in the Forced Swim Test and Tail Suspension Test, but had no significant effect on the Sucrose Preference Test and Novelty-Suppressed Feeding Test. - In the Open Field Test, J147 increased the time spent and the number of crossings in the central area, but had no significant effect on the number of rearing events. - **Neurochemical Analysis Results**: - J147 significantly increased the levels of 5-HT and NA in the prefrontal cortex and hippocampus, but had no significant effect on the levels of monoamine neurotransmitters in the amygdala. - J147 significantly inhibited MAO-A activity in the prefrontal cortex and hippocampus, but had a smaller effect on MAO-B activity. ### Conclusion: - J147 exhibits significant antidepressant and anxiolytic-like effects in subacute treatment, which may be related to its inhibition of MAO-A activity and the increase of monoamine neurotransmitter levels in the brain. This finding provides new insights for the further development of safe and effective antidepressants.